Radiochemical purification of no-carrier-added scandium-47 for radioimmunotherapy

Kolsky, K. L.; Joshi, Vishwas N.; Mausner, L.F.; Srivastava, Suresh C.

doi:10.1016/s0969-8043(98)00016-5

Cited by 87 publications

(75 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 The experimental results are lower than the theoretical ones, perhaps due to differences in the actual neutron spectrum when the irradiations occurred compared to the theoretical neutron spectrum. High production yields using the PTP positions at the HFIR were obtained.…”

Section: Severalmentioning

confidence: 84%

“…Both the Sc-46/Sc-47 and Sc-48/ Sc-47 impurity ratios are less than 0.4% at EOB (end of bombardment), leading to a product with greater than 99.5% radiopurity. 18,19 The specific activity of Sc-47 depends essentially on the scandium content of the enriched target material. Scandium is not a ubiquitous contaminant, such as lead or copper, and would not be expected to be introduced during processing of the target.…”

Section: Severalmentioning

confidence: 99%

“…These expectations were borne out when several product samples were analyzed with ICP-AE and no stable Sc was detected. 19 Since scandium was not detected in batches of target material, stable scandium content can be assumed to be the reported detection limit. The specific activities are high enough for antibody labeling applications in radioimmunotherapy.…”

Section: Severalmentioning

confidence: 99%

“…~150 kDa) given the measured specific activities. 19 Finally, it is necessary to recycle the expensive enriched target material to defray the target cost over many production runs. A simple procedure was developed that recovers 98.5% of the oxide based on precipitation of titanium at basic pH followed by conversion to the oxide using higher temperature.…”

Section: Severalmentioning

confidence: 99%

“…A simple procedure was developed that recovers 98.5% of the oxide based on precipitation of titanium at basic pH followed by conversion to the oxide using higher temperature. 19 Titanium may be recovered and easily reused since the only titanium activation product is the short lived Ti-51 (t½ = 5.8 minutes) produced by the 50 Ti(n, ) reaction using thermal neutrons. Other radionuclidic impurities that have been detected in recycled material are Ta-182 (t½ = 114.4 days) and Zn-65 (t½ = 244 days).…”

Section: Severalmentioning

confidence: 99%

See 4 more Smart Citations

A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals

Srivastava¹

2013

Journal of Postgraduate Medicine, Education and Research

View full text Add to dashboard Cite

This article deals primarily with the selection criteria, production, and the nuclear, physical, and chemical properties of certain dual-purpose radionuclides, including those that are currently being used, or studied and evaluated, and those that warrant future investigations. Various scientific and practical issues related to the production and availability of these radionuclides is briefly addressed. At brookhaven national laboratory (BNL), we have developed a paradigm that involves specific individual 'dual-purpose' radionuclides or radionuclide pairs with emissions suitable for both imaging and therapy, and which when molecularly (selectively) targeted using appropriate carriers, would allow pre-therapy low-dose imaging plus higher-dose therapy in the same patient. We have made an attempt to sort out and organize a number of such theragnostic radionuclides and radionuclide pairs that may thus potentially bring us closer to the age-long dream of personalized medicine for performing tailored low-dose molecular imaging (SPECT/CT or PET/CT) to provide the necessary pretherapy information on biodistribution, dosimetry, the limiting or critical organ or tissue, and the maximum tolerated dose (MTD), etc., followed by performing higher-dose targeted molecular therapy in the same patient with the same radiopharmaceutical. As an example, our preclinical and clinical studies with the theragnostic radionuclide Sn-117m are covered in somewhat greater detail.A troublesome problem that remains yet to be fully resolved is the lack of availability, in sufficient quantities and at reasonable cost, of a majority of the best candidate theragnostic radionuclides in a no-carrier-added (NCA) form. In this regard, a summary description of recently developed new or modified methods at BNL for the production of five theragnostic radionuclide/radionuclide pair items, whose nuclear, physical, and chemical characteristics seem to show promise for therapeutic oncology and for treating other disorders that respond to radionuclide therapy, is provided.

show abstract

Section: Severalmentioning

confidence: 84%

Section: Severalmentioning

confidence: 99%

Section: Severalmentioning

confidence: 99%

Section: Severalmentioning

confidence: 99%

Section: Severalmentioning

confidence: 99%

See 3 more Smart Citations

A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals

Srivastava¹

2013

Journal of Postgraduate Medicine, Education and Research

View full text Add to dashboard Cite

show abstract

Production of Therapeutic Radionuclides

Loveless

Lapi

2020

Handbook of Radiopharmaceuticals

View full text Add to dashboard Cite

Radiometals for imaging and theranostics, current production, and future perspectives

Mikołajczak

Meulen

Lapi

2019

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

The aim of this review is to make the reader familiar with currently available radiometals, their production modes, capacities, and quality concerns related to their medical use, as well as new emerging radiometals and irradiation technologies from the perspective of their diagnostic and theranostic applications. Production methods of 177Lu serve as an example of various issues related to the production yield, specific activity, radionuclidic and chemical purity, and production economy. Other radiometals that are currently used or explored for potential medical applications, with particular focus on their theranostic value, are discussed. Using radiometals for diagnostic imaging and therapy is on the rise. The high demand for radiometals for medical use prompts investigations towards using alternative irradiation reactions, while using existing nuclear reactors and accelerator facilities. This review discusses these production capacities and what is necessary to cover the growing demand for theranostic nuclides.

show abstract

Radiochemical purification of no-carrier-added scandium-47 for radioimmunotherapy

Cited by 87 publications

References 16 publications

A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals

A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals

Production of Therapeutic Radionuclides

Radiometals for imaging and theranostics, current production, and future perspectives

Contact Info

Product

Resources

About